Loading…
Co-Diagnostics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -99.6% over 5Y.
today you would have $3.73▼ -99.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $5.07 | $22.50 | $39.90 | $75.60 | |
| P/S | 6.2x | 17.1x | 6.3x | 6.1x | 2.3x |
| P/B | 0.5x | 0.5x | 0.5x | 0.5x | 0.7x |
| EPS | -$35.25 | -$37.22 | -$36.00 | -$13.50 | |
| Profit margin | -740.02% | -7533.62% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| XCURExicure Inc | $1.29 | — | 3.9x | — | -168.37% | $8.44M |
| MGRXMangoceuticals Inc | $0.40 | — | 0.6x | — | -95.10% | $8.67M |
| XWELXWELL, Inc. | $1.01 | — | 20.6x | — | -361.36% | $8.68M |
| EVGNEvogene Ltd. | $0.55 | — |
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
Company description provided by Yahoo Finance.
| -961.37% |
| -518.68% |
| -41.61% |
| ROE | -55.47% | -227.33% | -69.86% | -41.08% | -12.43% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| -182.75% |
| $8.68M |
| BMGLBasel Medical Group Ltd | $5.24 | — | 1.7x | — | -147.37% | $8.2M |
| NDRAENDRA Life Sciences Inc. | $5.80 | — | 1.4x | — | -152.04% | $8.7M |